The FDA's Most Polarizing Leader Just Walked Out the Door

Then came the personnel drama. Colleagues like Nicole Verdun clashed with Prasad publicly. By late February 2026, the FDA had opened a probe into allegations that Prasad retaliated against and verbally berated staff.

The July Saga: Fired, Then Un-Fired

Perhaps the strangest chapter played out in the summer of 2025. In July, Prasad was effectively removed from his role. But less than two weeks later, the FDA asked Prasad to come back, and he resumed the director's chair on August 11.

It was a bizarre episode that underscored just how divisive his leadership had become. Even the people who appointed him couldn't quite decide whether to keep him.

Two Sides of the Same Debate

The reactions to Prasad's exit reveal a genuine philosophical split in drug regulation.

Supporters of Prasad's approach argued his focus on evidence countered flexible approvals that inflate healthcare costs and burden programs like Medicare and Medicaid. In a world where some gene therapies carry price tags north of $2 million, that's not an abstract concern.

On the other side, biotech companies and some members of Congress saw Prasad's strict standards as arbitrary and unpredictable. Representative Jake Auchincloss voiced concerns about inconsistent decision-making under Prasad's watch.

Commissioner Makary, perhaps unsurprisingly, went with the diplomatic route. He praised Prasad's accomplishments and framed the exit as a planned return to family and academic life at UCSF.

What Changes Now?

This is where it gets interesting for anyone with a portfolio that includes biotech stocks or a medicine cabinet that relies on new treatments.

Makary's FDA has been pushing hard toward faster approvals. The agency's new default is requiring just one pivotal study for approval instead of the traditional two, a major shift from decades of practice. About 70–85% of novel drug approvals for rare and life-threatening diseases already relied on single studies; now that's the standard across the board. Add in AI-powered review processes, expanded use of real-world evidence, and efforts to phase out animal testing, and you can see the direction.

Prasad was a speed bump on that highway. Not necessarily in a bad way: speed bumps exist because the road can be dangerous. But his conservative stance on cell and gene therapies created friction with the administration's deregulatory "Make America Healthy Again" agenda.

With Prasad gone, the question becomes whether the FDA tilts further toward speed or finds someone who can balance efficiency with the kind of evidence standards that keep unsafe or useless drugs off the market. The choice of his replacement is being described as "make-or-break" for agency stability, and the announcement is expected before the end of April.

The Bigger Picture

The FDA approved 7 novel drugs by mid-March 2026, including Icotyde for psoriasis and Bysanti for schizophrenia. That's a solid pace, suggesting the agency's machinery is still grinding forward despite the leadership turbulence. But experienced reviewers have been leaving across both CBER and CDER, and forecasts suggest that staffing shortfalls could start affecting application reviews later this year.

Prasad once estimated that only about 9% of cancer patients respond to genomic drugs, a statistic he wielded to challenge the hype around precision oncology. That kind of intellectual honesty is valuable, even when it's uncomfortable. The hard part is delivering it without alienating every stakeholder in the building.

His departure doesn't settle the fundamental tension at the heart of drug regulation: how much evidence is enough? It's the biotech equivalent of asking how well you need to know someone before you marry them. Prasad wanted a long courtship. The industry wanted to elope. The next CBER director will inherit that debate, along with an agency that's been through a very rough year.

Whoever gets the job, one thing is certain: they'll have big shoes to fill and a lot of bruised egos to manage.